Document is current
Any future updates will be listed below
-
Authors
Weirauch, Ulrike
Kreuz, Markus
Birkenbihl, Colin
Alb, Miriam
Quaranta, Maria
Calzone, Laurence
Orozco-Ruiz, Sophia
Binder, Stefanie
Fischer, Luise
Clavreul, Solène
Maguri, Morine
Ferle, Maximilian
Rade, Michael
Azarias, Guillaume
Hydren, Jay R.
Jamarik, Jakub
Schwarz, Daniel
Sebestyen, Zsolt
Kuball, Jurgen
Popp, Georg
Antoine, Chloé
Knockaert, Manon
Schoeder, Clara T.
Fandrei, David
Sanges, Carmen
Radvilas, Vaclovas
Gagelmann, Nico
Rückert, Markus
Penack, Olaf
Fricke, Stephan
Schmidt, Andreas
Ward, Carol
Steinbeisser, Carl
Van Gyseghem, Jean-Marc
Niarakis, Anna
Garderet, Laurent
Hudecek, Michael
Neumuth, Thomas
Platzbecker, Uwe
Köhl, Ulrike
Demlova, Regina
Kremer, Andreas
Franke, Stefan
Fröhlich, Holger
Merz, Maximilian
Reiche, Kristin
,
Ferle, Maximilian
Van Gyseghem, Jean-Marc
Köhl, Ulrike
-
Funding
Funding for this research was provided by:
European Union (101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379, 101136379)
- License Information
-
More Information
Article History
Received: 30 August 2024
Accepted: 17 June 2025
First Online: 1 August 2025
Competing interests
: G.A. received speaker honoraria from Janssen Pharmaceutica NV. H.F. received funding from UCB Pharma and AbbVie for research purposes. S.Fri. received speaker's fees from Novartis Pharma GmbH, Janssen-Cilag GmbH, Vertex Pharmaceuticals (Germany) GmbH, Kite/Gilead Sciences GmbH, MSGO GmbH, Bristol-Myers Squibb GmbH & Co. KGaA and art tempi Communications. L.G.: Janssen, BMS, Sanofi, Pfizer. M.H. is an inventor on patent applications and has been granted patents related to CAR technology, licensed in part to industry. M.H. is a cofounder and equity owner of T-CURX GmbH, Würzburg. M.H. receives speaker honoraria from BMS, Janssen, Kite/Gilead, and Novartis and research support from BMS. J.R.H receives research funding from Adaptive Biotechnologies, BioLinRx, Sanofi, GlaxoSmithKline, Regeneron, Pfizer, Johnson and Johnson Innovative Medicine, and Takeda Oncology. U.K. has received consultant and/or speaker fees from AstraZeneca, Affimed, Glycostem, GammaDelta, Zelluna, CGT manufacturing: Miltenyi Biotec and Novartis Pharma GmbH, Bristol-Myers Squibb GmbH & Co. J.K. is shareholder on follow up companies of Gadeta, inventor on multiple patents dealing with genetic engineering of immune cells, received research support from Novartis, Miltenyi Biotech, and Gadeta. Maximilian Merz: Advisory Boards/Honoraria/Research support: Amgen, BMS, Celgene, Gilead, Janssen, Stemline, Springworks, Takeda, and Roche/Genentech. A.N. collaborates with SANOFI-AVENTIS R&D via a public–private partnership grant CIFRE contract, n° 2020/0766. O.P. has received grants and personal fees from Incyte, Neovii, Gilead, Merck Sharpe and Dohme, Omeros, Sobi, Takeda, and Jazz Pharmaceuticals. U.O. has received honoraria and research support from BMS, Johnson-Johnson, Gilead. A.S. is a shareholder and managing director of Springboard Health Angels, Schmidt Deng Ventures and their respective venture funds and portfolio companies. D.S. is shareholder at Masaryk University spinoff: Institute of Biostatistics and Analyses. Z.S. is inventor on multiple patents dealing with genetic engineering of immune cells. K.R. received honoraria from Novartis Pharma GmbH. The other authors declare no competing interests.
